EUCTR2014-004904-31-NL
Active, not recruiting
Phase 1
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.
ConditionsCrohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).Therapeutic area: Diseases [C] - Immune System Diseases [C20]
DrugsRemsima (infliximab)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).
- Sponsor
- Mundipharma Pharmaceuticals B.V.
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female, age \=18 years.
- •2\.Subject will have a confirmed diagnosis of RA, UC or CD.
- •3\.Stable remission defined as HBI\=4, SCCAI\<3, DAS 28\<3\.2 at screening.
- •4\.Stable and continuous treatment with Remicade during the last 30 weeks, and no foreseen dose adjustment for the coming 2 months for infliximab.
- •5\.Stable concomitant treatment; if concomitant drugs than stable for 4 months and no foreseen changes in drugs.
- •For RA: stable and continuous treatment with MTX.
- •6\.Non\-pregnant, non\-nursing female.
- •7\.Subject capable of understanding and signing an informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •1\.Subjects with evidence of the following major co\-morbidities such as: severe diabetic mellitus, tuberculosis (TB), severe infections, uncontrollable hypertension, severe cardiovascular disease (New York Heart Association \[NYHA] class 3 or 4\) and/or severe respiratory diseases.
- •2\.Any other condition/disease, which in the opinion of the investigator makes the subject ineligible for the study.
- •3\.Any clinically relevant hypersensitivity to (anaphylaxis or infusion related reactions) infliximab or to other murine proteins
- •4\.Change of major co\-medication during the last 4 months prior to screening and foreseen dose adjustment during the next 2 months:
- •RA: Initiation of systemic corticosteroids or synthetic DMARDs or other medication, which according to the investigator would interfere with the stability of the disease.
- •UC and CD: Initiation of systemic corticosteroids or an immunosuppressant or other medication, which according to the investigator would interfere with the stability of the disease.
- •5\.Change in treatment with Remicade during the last 30 weeks due to disease related factors, not including dose/frequency adjustments due to serum infliximab concentration measurements.
- •6\.Simultaneous treatment with another biological or a not registered NCE.
- •7\.Psychiatric or mental disorders, alcohol abuse or other substance abuse (and/or history of opioid abuse), language barriers or other factors which makes adherence to the study protocol impossible.
- •8\.Inadequate birth control, pregnancy, and/or breastfeeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.EUCTR2014-004904-31-BEMundipharma Pharmaceuticals B.V.156
Completed
Phase 4
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima* (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn*s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.Reumatoid Arthritis/RheumatismCrohn's Disease/Inflammatory Bowel Disease (IBD)Colitis Ulcerosa/IBD1001796910003816NL-OMON43846Mundipharma129
Active, not recruiting
Phase 1
ong-term hepatitis A and B antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-084 (208127/084).Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults)MedDRA version: 16.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-004586-13-CZGlaxoSmithKline Biologicals s.a.180
Completed
Not Applicable
Persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and response to the Hib-MenC (Menitorix®) vaccine in healthy childreMeningococcal C and Haemophilus influenzae type B diseasesInfections and InfestationsISRCTN72858898niversity of Oxford (UK)250
Active, not recruiting
Not Applicable
Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®.Healthy volunteers (Vaccination against hepatitis A in healthy adults)MedDRA version: 16.1Level: LLTClassification code 10052551Term: Hepatitis A virusSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-001918-15-BEGlaxoSmithKline Biologicals